It will be important to investigate if there is a direct and inverse correlation between sortilin and syndecan-1 and to establish if there is either a molecular switch or an alternative mechanistic explanation for the alignment of these biomarkers with different stages of prostate cancer progression. This evidence concerns the gene SORT1 and prostate carcinoma.